Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Prelude Therapeutics Incorporated (PRLD)
Company Research
Source: GlobeNewswire
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. “Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team,” stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. “We welcome her to our board and we look forward to her immediate contributions as we aim to advance our precision oncology drug candidates.” Ms. Dorton was most recently Chief Financial Officer at NodThera. Prior to NodThera, she most recently built and led the finance organization for Repare Therapeutics, where she prepared the company for an IP
Show less
Read more
Impact Snapshot
Event Time:
PRLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRLD alerts
High impacting Prelude Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
PRLD
News
- PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law FirmGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLDPR Newswire
- PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law FirmGlobeNewswire
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
PRLD
Earnings
- 11/12/25 - Beat
PRLD
Analyst Actions
- 9/23/25 - HC Wainwright
PRLD
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 11/7/25 - Form 4
- PRLD's page on the SEC website